Tvardi Therapeutics, Inc. Common Stock (TVRD)

• Market cap: $230M
• 1 day: -5.71%
• 5 days: -16.40%
• 1 month: -7.23%
• 3 months: 386.56%
• 6 months: 684.08%
• Year to date: 359.33%
• 1 year: 362.78%
• 5 years: -86.78%
• 10 years: -81.04%
• Sector: Healthcare
• Industry: Biotechnology

About: Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

11.86% more ownership

Funds ownership: 2.0% [Q4 2024] → 13.86% (+11.86%) [Q1 2025]

17% less funds holding

Funds holding: 41 [Q4 2024] → 34 (-7) [Q1 2025]

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

51% less capital invested

Capital invested by funds: $6.59M [Q4 2024] → $3.21M (-$3.38M) [Q1 2025]

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $39 58% upside
• Avg. target: $61 146% upside
• High target: $78 217% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Yasmeen Rahimi	217% upside $78	Overweight Initiated	12 Jun 2025
Oppenheimer Jay Olson	164% upside $65	Outperform Initiated	21 May 2025
Jones Trading Debanjana Chatterjee	58% upside $39	Buy Initiated	28 Apr 2025